Alpelisib
| CAS No. | 1217486-61-7 | Cat. No. | BCP06730 |
| Name | Alpelisib | ||
| Synonyms | NVP-BYL719; NVP-BYL-719; NVP-BYL 719;BYL-719;BYL 719;BYL719; | ||
| Formula | C19H22F3N5O2S | M. Wt | 441.47 |
| Description | Alpelisib, also known as BLY719, is an orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Alpelisib is equipotent against both wild type and several mutant isoforms (IC50s = 4.0-4.8 nM). eCollection 2020. Navitoclax combined with Alpelisib effectively inhibits Merkel cell carcinoma cell growth in vitro. Alpelisib Plus Letrozole Shows Promise After CDK 4/6 Inhibitor Therapy in PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer. | ||
| Pathways | PI3K/Akt/mTOR | ||
| Targets | PI3K | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.